A Retrospective, cohort study to evaluate the unaffected retinal vessel diameter after intravitreal bevacizumab injection in patients with macular edema secondary to branch retinal vein occlusion (BRVO)
Latest Information Update: 18 Apr 2017
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Branch retinal vein occlusion; Retinal oedema
- Focus Therapeutic Use
- 18 Apr 2017 New trial record